Evidence map›Paper›PMID 40533702›Full record

SynthesisQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2025

A systematic review of patient-reported outcome measures (PROMs) to assess health-related quality of life (HRQoL) for breast cancer patients who are undertaking adjuvant endocrine therapy.

Rila Su, Claire Snyder, Albert W Wu, Alden L Gross, Jiafu Ji, Jiaming Zhang, Laura Morlock

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rila SuDepartment of Oncology, Inner Mongolia People's Hospital, Hohhot, Inner Mongolia, China.ORCID http://orcid.org/0000-0002-0299-4390
Claire SnyderDepartment of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-8952-4561
Albert W WuDepartment of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-6189-7120
Alden L GrossDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-4678-0562
Jiafu JiState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, GI Cancer Center of Peking University Cancer Hospital & Institute, Beijing, China.
Jiaming ZhangGraduate School of Inner, Mongolia Medical University, Hohhot, Inner Mongolia, China.
Laura MorlockDepartment of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. lmorloc1@jhu.edu.

Funding

Inner Mongolia Academy of Medical Science 2023GLLH0008Natural Science Foundation of Inner Mongolia Autonomous Region 2022MS08079Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCI P30CA006973
6 · The paper itself

Abstract

purposeBreast cancer (BC) is the most prevalent cancer among women, with hormone receptor-positive BC making up approximately 70% of cases. Adjuvant Endocrine Therapy (AET) is critical in reducing recurrence in this patient population. Still, it often leads to side effects that negatively impact patients' health-related quality of life (HRQoL). Patient-reported outcome measures (PROMs) are widely used to assess HRQoL, but there is inconsistency in the instruments used to evaluate the impact of AET on BC patients. This systematic review aimed to identify and evaluate PROMs that assess HRQoL in BC patients undergoing AET, using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) guidelines.

methodsA systematic search was conducted across MEDLINE, EMBASE, Cochrane Library, and Google Scholar for studies published between 2007 and 2023. Studies that developed and validated PROMs for BC patients on AET were included. The measurement properties of each PROM were appraised following COSMIN guidelines, and their relevance, comprehensiveness, and comprehensibility were assessed.

resultsThe review included 24 studies assessing six PROMs. The European Organization for Research and Treatment of Cancer-Breast Cancer45 (EORTC BR45) and Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) demonstrated sufficient content validity and covered the majority of AET-related symptoms. Both instruments were rated highly for structural validity, internal consistency, cross-cultural validity, and reliability. FACT-ES also demonstrated strong responsiveness to treatment-related changes.

conclusionsEORTC BR45 and FACT-ES are the most suitable PROMs for assessing HRQoL in BC patients undergoing AET due to their robust psychometric properties and comprehensive coverage of AET-related symptoms.

Indexed as

Antineoplastic Agents, HormonalBreast NeoplasmsPatient Reported Outcome MeasuresQuality of LifeChemotherapy, AdjuvantFemaleHumansMiddle AgedAntineoplastic Agents, HormonalAdjuvant endocrine therapyBreast cancerCOSMIN analysisPROMsPsychometric properties

Identifiers

PMID40533702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.